Two COPD 3 drugs combi inhalers that are competing for reimbursement are not easily able to get out of the HIRA stage. AstraZeneca's 'Breztri Aerosphere' also requested a re-evaluation of the committee's results, while Kolon Pharmaceutical's 'Trimbow Inhaler' took on a re-challenge for reimbursement despite the drug evaluation committee's conditional decision. According to the industry on the 4th, Breztri Aerosphere, which was notified of the conditional determination of the adequacy of benefits when accepting less than the appraised amount at the 5th committee last May, recently applied for re-evaluation. According to the drug reimbursement evaluation regulations, drug manufacturers, etc. may apply for re-evaluation